Subcutaneous Ofatumumab for remission maintenance in pediatric idiopathic nephrotic syndrome: a case series

Clicks: 2
ID: 314849
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #102 of 128 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 128 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Rituximab (RTX) is effective for pediatric frequently-relapsing or steroid-dependent nephrotic syndrome (FR/SDNS); however, some patients develop RTX resistance or severe hypersensitivity. Ofatumumab (OFA), a fully humanized anti-CD20 monoclonal antibody, represents a potential alternative, yet its use in children remains poorly documented.This study evaluates the feasibility and safety of low-dose subcutaneous (SC) OFA in children with complicated FR/SDNS who are RTX-resistant or intolerant. Methods We retrospectively analyzed five pediatric patients (median age 14.8 years) with FR/SDNS and a history of RTX resistance or hypersensitivity. Each patient received a standardized SC OFA dose of 20 mg. B-cell depletion (CD19⁺ <1%), serum IgG levels, and adverse events—graded according to the Common Terminology Criteria for Adverse Events (CTCAE)—were monitored throughout follow-up. The primary endpoint was relapse-free remission within 12 months of the last OFA dose. Results SC OFA achieved peripheral B-cell depletion in all patients, with a median duration of 5 months. Within 12 months, 80% (4/5) of patients maintained remission. One patient with previous severe anti-CD20 hypersensitivity tolerated SC OFA with mild (Grade 2) symptoms after ibuprofen premedication. No severe infections or exacerbations of hypogammaglobulinemia were documented. Conclusions Low-dose SC OFA is a feasible preemptive therapy for remission maintenance in pediatric FR/SDNS, particularly for those with RTX resistance or intolerance. This outpatient-compatible route may reduce hypersensitivity risks and healthcare costs. Larger prospective trials are warranted to confirm long-term efficacy.
Reference Key
openalex_W7162333445 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Na Cui, Shi-Yi Zhu, Ruyue Chen, Shuang Wu, Qiang Lin, Zhu Y, LI Xiao-zhong
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag169
URL
https://doi.org/10.1093/ckj/sfag169
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.